Skip to main content
. 2021 Apr 27;14:1185–1192. doi: 10.2147/JPR.S244249

Table 2.

The Results of the Efficacy Primary Endpoints in ACHIEVE I and ACHIEVE II1,2

ACHIEVE I Placebo 50 mg 100 mg
% of patients with freedom from pain at 2 hours (moderate/severe pain to 0 pain) 11.8% 19.2% (p=0.002) 21.2% (p< 0.001)
% of patients with absence of the most bothersome migraine-associated symptom (photophobia, phonophobia, nausea) 27.8% 38.6% (p=0.002) 37.7% (p=0.002)
ACHIEVE II Placebo 25 mg 50 mg
% of patients with freedom from pain at 2 hours (moderate/severe pain to 0 pain) 14.3% 20.7% (p=0.03) 21.8% (p=0.01)
% of patients with absence of the most bothersome migraine-associated symptom (photophobia, phonophobia, nausea) 27.4% 34.1% (p=0.07) 38.9% (p=0.01)